Feb 25 (Reuters) - Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well ...

In the latest trading session, Gilead Sciences (GILD) closed at $147.83, marking a -1.46% move from the previous day.

Wall Street is mired in another panic over AI. And we contrarians are here for it. Our play? This closed end fund yielding ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsJohanna Mercier - Chief ...

The inaugural direct-to-consumer campaign for the injectable drug debuted earlier this year, centering around a TV ad featuring a remake of Ciara and Missy Elliott’s 2004 hit song “1, 2 Step”—now ...

Poor shooting and untimely fouls ultimately doomed the Bowling Green Christian Academy’s varsity boys basketball team on ...

The VDH has not answered questions about how much money it erroneously overbilled a pharmaceutical manufacturer and may have to pay back, despite the issue triggering significant cuts to HIV services.

Merck's blockbuster immunotherapy Keytruda, which generates nearly half of its total revenue, is scheduled to lose U.S. patent protection in 2028, opening the door to lower-cost generic competition.

As Gilead Sciences has outperformed its sector peers recently, analysts remain highly optimistic about the stock’s prospects.

GILEAD FOUNDATION AWARDS $12 MILLION TO EMPOWER COMMUNITY HEALTH WORKERS AND EXPAND HIV PREVENTION INITIATIVES ACROSS THE US ...

It's designed to take the place of complicated, multiple drug regimens that many people with HIV need to follow. And it's ...

Gilead has released new phase 3 data from its ARTISTRY‑1 and ARTISTRY‑2 trials assessing treatment responses in adults with HIV who are virologically suppressed, including those switching from complex ...